Skip to main content
OpenTrials
Completed

NCT Number: NCT06872814

Vaccine Hesitancy in Patients with Solid Tumors: a Cross-sectional Single-center Survey

Cancer patients have a well-known and higher risk of vaccine-preventable disease (VPD) than the general population. VPD can cause serious complications due to compromised immune system, malnutrition and the same oncology treatments and represent a severe financial burden with a delay in treating the underlying cancer The main purpose of this survey is to analyse the perception of cancer patients on the topic vaccines and vaccine-preventable diseases, the acceptability of vaccines and the evaluation of the determining factors associated with the choice of the patient to be vaccinated or not. This information will be used to improve the management of these issues.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Patients Infections Vaccine-Preventable Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione IRCCS Policlinico San Matteo, SC Oncologia

Pavia, 27100, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >18 years of age;
  • Oncology patient defined as a patient with solid tumors undergoing active systemic treatment or follow-up;
  • Written informed consent

Exclusion criteria

  • Patients with hematological tumors
  • Patients who are unable to understand informed consent document

Treatment and study plan

Primary outcomes

  1. assess the proportion of vaccinated subjects in our cohort of cancer patients undergoing active cancer treatment

    Time frame: 3 months

    The primary endpoint will be to assess the proportion of vaccinated subjects in the investigators cohort of cancer patients undergoing active cancer treatment (number of patients who received at least one vaccine/ total number of patients)

Secondary outcomes

  1. assess the proportion of vaccinated subjects with the anti flu vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

    Time frame: 3 months

  2. assess the proportion of vaccinated subjects with anti SARS-CoV-2 vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

    Time frame: 3 months

  3. assess the proportion of vaccinated subjects with anti pneumococccal vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

    Time frame: 3 months

  4. assess the proportion of vaccinated subjects with anti HZ vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

    Time frame: 3 months

  5. assess which variables (sex, age, degree of education, marital state, commodities, type of tumor, type of oncological treatment) are associated with not willingness to receive vaccines

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Other

Registry information

Acronym: VE

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Mar 12, 2025
Registry last updated
Mar 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.